Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Written By: Nitin Goswami, Senior Medical Content Writer | Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Quick answer: Von Hippel-Lindau (VHL) disease is a rare inherited condition, caused by a change in the VHL gene, that leads to tumors and cysts in the kidneys, brain and spinal cord, eyes, pancreas, adrenal glands, and inner ear. It affects roughly 1 in 36,000 people. Care combines regular surveillance, surgery, and, for eligible adults, the oral medicine Welireg (belzutifan). Welireg isn't yet sold in India, but it can be accessed legally through a Named Patient Program with a valid prescription.
Last reviewed: September 24, 2026. Sources are listed in the References section at the end.
Hearing the words "Von Hippel-Lindau disease" for the first time is unsettling, mostly because almost nobody has heard of it before a diagnosis lands on their own family. It is not a single tumor or a single cancer. It is a rare genetic condition that quietly raises the risk of tumors and cysts forming in several organs at once — the kidneys, brain, spinal cord, pancreas, eyes, ears and adrenal glands — sometimes years apart, sometimes all around the same time. If you or someone you love has just been told "you carry a VHL gene mutation," this guide walks through what that actually means, what to watch for, and what treatment — including newer options like belzutifan (Welireg) — looks like today.
| Condition | Von Hippel-Lindau (VHL) disease, an inherited condition with an autosomal dominant inheritance pattern |
|---|---|
| Cause | A mutation in the VHL gene, located on chromosome 3 |
| How common | Roughly 1 in 36,000 people (MedlinePlus Genetics) |
| Organs affected | Kidneys, brain and spinal cord, pancreas, eyes, adrenal glands, and inner ear |
| Care options | Regular surveillance, surgery, and Welireg (belzutifan) |
| Medicine | Welireg (belzutifan), an oral HIF-2α inhibitor made by Merck Sharp & Dohme, in 40 mg film-coated tablets. First approved in the U.S. in 2021 |
| Approved use in VHL | Adults with VHL disease who need treatment for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors that do not need immediate surgery |
| Key monitoring | Anemia and oxygen levels (hypoxia) during Welireg treatment, plus regular imaging and eye exams for VHL surveillance |
| Access in India | Welireg isn't yet sold in India. It can be accessed through a Named Patient Program with a valid prescription (see the Welireg product page) |
Von Hippel-Lindau disease is an inherited disorder caused by a fault in a single gene — the VHL gene — that normally acts as a tumor suppressor. Think of a tumor suppressor gene as a built-in brake pedal: its job is to stop cells from growing and dividing out of control. When the VHL gene stops working properly, that brake pedal fails in certain cell types, and clusters of blood vessels or abnormal cells can begin forming into tumors or fluid-filled cysts.
VHL disease affects roughly 1 in 36,000 people worldwide, which is why most general physicians will only ever see a handful of cases — or none — in an entire career. That rarity is exactly why an accurate, early diagnosis matters so much: the condition is manageable when it is monitored and treated proactively, but it is easy to miss if nobody is looking for the pattern.
VHL is rare, and rare diseases are hard to count. The figures below come from published studies and public-health resources, with the source named for each.
Figures differ between studies because patients are followed for different lengths of time, so treat these as examples rather than fixed rates:
These are modelled estimates for groups, not predictions for an individual — but they reflect why regular surveillance and early treatment are so strongly recommended.
Every VHL disease case traces back to a mutation in the VHL gene, located on chromosome 3. This gene's normal job is to help break down a protein called HIF (hypoxia-inducible factor), which cells use to sense low-oxygen conditions. When VHL is faulty, HIF builds up even when oxygen levels are normal, tricking cells into behaving as if they are starved of oxygen. That triggers abnormal blood vessel growth and cell proliferation — the biological root of the tumors seen in VHL disease.
VHL disease follows an autosomal dominant inheritance pattern. In practical terms, that means:
Yes. In about 1 in 5 cases, the VHL gene mutation is brand new — a spontaneous ("de novo") change that occurs at conception, with no prior family history at all. So the absence of a family history should never rule out VHL disease if the clinical pattern of tumors fits.
What makes VHL disease unusual is how many different organs can be involved. Not every patient develops every feature, and the age of onset varies widely, but here is the recognized pattern at a glance:
Here is what each of these means in practice:
Kidney cysts are extremely common in VHL disease and are usually harmless on their own. The bigger concern is clear cell renal cell carcinoma (RCC), the most frequent cause of death in VHL disease if left unmonitored. Because RCC tumors linked to VHL tend to be multiple and to recur in both kidneys over time, care focuses on delaying surgery for as long as it is safely possible rather than operating on every small tumor.
Hemangioblastomas are benign (non-cancerous) tumors made of tangled blood vessels. They are the most common tumor type in VHL disease and typically form in the cerebellum, brainstem or spinal cord. They rarely spread, but their location means even a benign hemangioblastoma can press on critical nerve tissue and cause real symptoms.
Pancreatic cysts are usually silent and require no treatment. Pancreatic neuroendocrine tumors (pNETs), however, need regular imaging because a subset can grow large enough, or show high-risk features, to require intervention.
These are the same type of blood-vessel tumor found in the brain, but forming on the retina. Left unchecked they can cause retinal detachment or vision loss, which is why regular dilated eye exams are part of standard VHL surveillance from childhood onward.
Pheochromocytomas are tumors of the adrenal gland that can release excess adrenaline-type hormones, causing episodes of high blood pressure, pounding headaches, sweating and a racing heartbeat. They can also occur outside the adrenal gland, where they are called paragangliomas (together, PPGL).
A less common but important feature — these tumors can cause hearing loss, ringing in the ears (tinnitus) or balance problems, and are often overlooked until hearing symptoms prompt an ENT referral.
Because VHL disease can involve so many organs, symptoms depend entirely on which tumors are active at a given time. There is no single "VHL symptom" — instead, watch for patterns like:
Many people with VHL disease have no symptoms at all for years and are only picked up through family screening after a relative's diagnosis — another reason genetic testing matters even when someone feels completely well.
A blood test that sequences the VHL gene can confirm the diagnosis directly and is the most reliable way to test at-risk relatives, including children, before any tumors have formed.
Once VHL disease is confirmed or strongly suspected, doctors follow a structured, lifelong surveillance schedule. A typical protocol includes:
The exact schedule and starting age are individualized based on family history and prior findings.
VHL disease cannot be cured at the gene level today, but nearly every complication it causes is manageable when caught early. A 2 cm kidney tumor found on a routine scan can often be watched safely; the same tumor found only after it causes symptoms may already need surgery or systemic treatment. This is the entire logic behind lifelong surveillance — it turns VHL disease from an unpredictable threat into a condition that can be actively managed on the patient's terms.
For decades, the mainstay of VHL disease management was watchful waiting followed by surgery once a tumor crossed a size or risk threshold — removing a kidney tumor, resecting a brain hemangioblastoma, or draining a troublesome cyst. This approach still has an important place today, especially for solitary, surgically accessible tumors.
The more recent development in VHL disease care is Welireg (belzutifan), the first oral medicine specifically studied and approved for VHL disease-associated tumors. Instead of removing tumors surgically, it works at the biological source of the problem.
Belzutifan is a HIF-2α inhibitor. Recall that a faulty VHL gene allows HIF to build up abnormally, driving tumor blood vessel growth. Belzutifan directly blocks HIF-2α, effectively re-installing the "brake" that the mutated VHL gene can no longer provide. In clinical studies, this shrank VHL-associated kidney tumors, brain hemangioblastomas and pancreatic neuroendocrine tumors in a meaningful proportion of patients, often delaying or avoiding surgery altogether.
Welireg's approved uses now span several tumor types driven by the same underlying biology:
Side effects can differ slightly depending on which condition is being treated:
For VHL disease-associated tumors:
For advanced renal cell carcinoma:
Your care team will check blood counts and metabolic panels regularly and may adjust the dose, pause treatment temporarily, or stop it altogether if side effects become significant.
Two risks in particular need active monitoring, and your treating oncologist will explain both in detail before starting therapy.
Belzutifan can cause serious harm to a developing fetus, so it is not used during pregnancy. Both females who can become pregnant and males with partners who can become pregnant are advised to use effective non-hormonal contraception during treatment and for one week after the last dose, since belzutifan can also make hormonal birth control less effective.
Because belzutifan can cause significant anemia and, less commonly, low blood oxygen levels, your doctor will check blood counts and oxygen saturation before starting treatment and at regular intervals afterward, particularly in the first weeks of therapy.
Welireg is not yet commercially marketed in India, which understandably worries families who have just found a treatment that could genuinely help. It can still be legally imported for personal patient use through a Named Patient Program — a regulated pathway that allows a patient with a valid prescription from a treating doctor to import an approved-abroad medicine that isn't yet sold locally. Typically, this involves:
If you are exploring this route for VHL disease, the Welireg product page outlines the current process, and our rare disease access program covers how the same import pathway supports other genetic and rare conditions.
A VHL disease diagnosis is a lifelong one, but it is not a fixed script. Outcomes have improved substantially over the last two decades because of earlier genetic testing, structured surveillance, and now targeted medical therapy that can reduce how often surgery is needed. Many people with VHL disease work, raise families and lead full lives — the difference between a good outcome and a difficult one is almost always consistent, lifelong follow-up rather than any one dramatic intervention. If VHL disease runs in your family, genetic counseling for siblings, children and extended relatives is one of the most protective steps you can take, since it turns future tumors into something caught early rather than discovered late.
Not by itself. VHL disease is a genetic condition that raises the risk of certain tumors, some benign (like hemangioblastomas) and some malignant (like renal cell carcinoma). Whether a specific tumor is cancerous is assessed case by case.
There is currently no cure at the gene level, but it is a manageable condition. Surgery, surveillance and targeted medicines like belzutifan allow most complications to be controlled effectively over a person's lifetime.
It varies widely, but retinal and CNS hemangioblastomas often appear earliest, sometimes in the teenage years, while kidney and pancreatic involvement more commonly shows up in the 20s to 40s. This is why surveillance typically starts in childhood for anyone with a confirmed VHL gene mutation.
Yes, especially if a close relative has been diagnosed. VHL disease often causes no symptoms in its early stages, and genetic testing is the only reliable way to know whether surveillance is needed before a tumor ever forms.
Belzutifan is not a chemotherapy drug. It's a targeted oral therapy that blocks a specific protein pathway (HIF-2α) that drives tumor growth in VHL disease, rather than broadly attacking all rapidly dividing cells the way traditional chemotherapy does.
Through a regulated Named Patient Program, which allows import of the medicine for a specific, named patient with a valid prescription and the required medical and regulatory documentation — a legal pathway used worldwide for medicines not yet locally marketed.
VHL disease is lifelong, so belzutifan may be taken for a long time — which makes the reliability of every batch important. Sellers outside regulated channels can supply counterfeit, expired, or incorrectly stored tablets that look the same as genuine ones, and there is no easy way for a patient to tell the difference. Named Patient Program sources against a valid prescription, directly from the manufacturer or its authorized distributors, with documentation and batch traceability at each stage, so the medicine that reaches you is genuine.
This article is intended to explain VHL disease and its treatment options in plain language. It can't replace a consultation with your own doctor or a genetics specialist, who can interpret your specific results and medical history.
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.com
Contact Us:
+91 9810469557
We get back to you shortly during our working hours.